IMPORTANT SAFETY INFORMATION INCLUDING BOXED WARNING AND INDICATION
Choose a patient story
Discover if you could benefit from a different approach to treatment.
Richard
42 years old
With aggressive disease
View profile
Patrick
71 years old
With bulky disease
Anna
61 years old
Undergone a series of treatments
Sam
58 years old
Eligible for a stem cell transplant
Marie
64 years old
Hesitant to continue any treatment
ELARA: A pivotal, global open-label, multicenter, single-arm phase II trial in adult patients with R/R FL
Note: These are fictitious patients.
CAR, chimeric antigen receptor; CD, cluster of differentiation; CRR, complete response rate; DOR, duration of response; FL, follicular lymphoma; HSCT, hematopoietic stem cell transplant; IRC, Independent Review Committee; IV, intravenous; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; r/r, relapsed/refractory. aDisease was reassessed prior to infusion for all patients requiring bridging therapy.1 bInfusion was administrated in an inpatient or outpatient setting at investigator discretion.1 cRefractory to ≥2nd line of systemic therapy (including an anti-CD20 antibody and alkylating agent) or relapsed within 6 months after ≥2nd line of therapy or after an autologous HSCT.1 References: 1. Dreyling M et al. Presented at: 64th American Society of Hematology Annual Meeting; December 10-13, 2022; New Orleans, LA. Abstract 608. 2. Kymriah [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.
Patient Stories Richard's Story Patrick's Story Anna's Story Sam's Story Marie's Story
Patient Selector Richard's Story Patrick's Story Anna's Story Sam's Story Marie's Story
Patient stories
Meet Richard, a patient with aggressive disease
Treatment History
1st Round
R-CHOP
Responded well at first but, after 18 months, the lymphoma came back
2nd Round
Second-line R-Benda
Treatment did not work
Could KYMRIAH help patients like Richard?
Richard may be eligible for a stem cell transplant.
R-CHOP and R-Benda are cancer drug combinations used to treat follicular lymphoma.R-Benda, rituximab and bendamustine; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
My Story
“My name is Richard and I’m 42 years old. I’m a carpenter who loves to stay active. But, 2 years ago I was diagnosed with grade 2 follicular lymphoma. Dealing with my treatment can be tough because it makes it hard for me to keep working and be physically active. I'm worried about how aggressive my cancer might be, and I sometimes feel like finding a treatment that works might not be possible.”
Traditional chemotherapy often does not work in patients with aggressive disease. Patients who have relapsed or refractory FL and are eligible for stem cell transplantation may also be a good fit for CAR-T cell therapy.
1
2
How KYMRIAH may help
Find out how KYMRIAH may help
Around 1 in 5 patients with FL have aggressive disease like Richard.
References: 1. Casulo C et al. J Clin Oncol. 2015;33(23):2516-2522. 2. Kase AM et al. Clin Case Rep. 2022;10(4):e05572.
Responded well but, after 3 years, the lymphoma returned
R-Mono
Responded well but, after 9 months, the lymphoma returned. Therefore, Patrick is not eligible for a stem cell transplant
Could KYMRIAH help patients like Patrick?
R-CHOP and R-Mono are cancer drug combinations used to treat follicular lymphoma. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-Mono, rituximab monotherapy.
Patients with bulky disease in their body have a higher chance of the disease spreading quickly and have a less favorable outlook than those without bulky disease.
References: 1. Gogia A et al. Asian Pac J Cancer Prev. 2017;18(3):681-685. 2. Ghielmini M et al. Ann Oncology. 2013;24(3):561-576. 3. Pavanello F et al. Mediterr J Hematol Infect Dis. 2016;8(1):e2016062.
Up to 1 in 5 patients with FL have bulky disease like Patrick.
1- 3
Meet Patrick, a patient with bulky disease
FLIPI, or Follicular Lymphoma International Prognostic Index, is a tool used by oncologists that helps predict patient survival based on the following clinical information: age, stage, LDH and hemoglobin levels, and number of nodal areas.
“I’m Patrick. I’m 71 years old and a retired teacher. I have a large family that I love spending time with, especially my grandchildren. Five years ago, I was diagnosed with follicular lymphoma (FL). My cancer is in the advanced stage (grade 3), and I have bulky disease (over 7 cm). I’m considered high risk for traditional chemotherapy not working because the FL affects more than 5 parts of my body, and the test results show that the disease is very active with increased lactate dehydrogenase (LDH) and a Follicular Lymphoma International Prognostic Index (FLIPI) score of 4. I also have an enlarged spleen which causes discomfort and pain in my stomach.”
Did not respond to treatment
R-Benda
Ibritumomab tiuxetan
R-CHOP and R-Benda are cancer drug combinations used to treat follicular lymphoma. R-Benda, rituximab and bendamustine; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
“I am Anna, a 61-year-old sales manager at a publishing company. Four years ago, I was diagnosed with follicular lymphoma (FL). I lead an active life and one of my favorite things to do is to walk my dogs every day. But lately, I have been feeling frustrated because I have tried several treatments for the FL, and none of them have worked. I fear that I may never be able to achieve remission. The treatments have also caused me side effects such as nausea, constipation, and tiredness, and the FL has not responded to traditional chemotherapy or immunotherapy.”
Reference: 1. Batlevi CL et al. Blood Cancer J. 2020;10(7):74.
Each time a patient goes through a round of treatment, the chances of it being successful decrease.
Meet Anna, a patient who has undergone a series of treatments
3rd Round
4th Round
Stem cell transplant
Lymphoma returned
Could KYMRIAH help patients like Anna?
Reference: 1. Kase AM et al. Clin Case Rep. 2022;10(4):e05572.
Patients who have relapsed or refractory FL and are eligible for stem cell transplantation may also be a good fit for CAR-T cell therapy.
Responded well, but the lymphoma returned after 36 months
R-CVP
Could KYMRIAH help patients like Sam?
Sam may be eligible for a stem cell transplant.
R-CHOP and R-CVP are cancer drug combinations used to treat follicular lymphoma. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab, cyclophosphamide, vincristine, and prednisone.
“I am Sam, a 58-year-old architect. I live with my wife and our three teenage children. More than three years ago, I was diagnosed with follicular lymphoma (FL). My wife made the decision to leave her job to take care of me and to be able to accompany me to all my appointments. I am grateful for her love and support during this time.”
Meet Sam, a patient eligible for a stem cell transplant
Treatment delayed, then stopped after 3 cycles due to side effects
R-Lenalidomide
Treatment stopped due to side effects
Could KYMRIAH be the right choice for Marie?
Marie is eligible for a stem cell transplant but she is reluctant because it involves a high dose of chemotherapy.
R-CHOP and R-Lenalidomide are cancer drug combinations used to treat follicular lymphoma. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; R-Lenalidomide, rituximab and lenalidomide.
“I am Marie, a 64-year-old secretary. Unfortunately, I had to take some time off from work because of my health. Four years ago, I was diagnosed with follicular lymphoma (FL). Dealing with my treatment can be very hard and it can be a lot to handle. I struggle keeping up with the treatment schedule and the side effects can be overwhelming. I often feel tired, weak, and short of breath. Sometimes, I just need a break from it all.”
Meet Marie, a patient who is hesitant to continue any treatment
